Microbiome Therapeutics Market Size to Reach USD 1,713.2 Million in 2032
The Microbiome Therapeutics Market size was USD 176.4 Million in 2024 and is expected to register a revenue CAGR of 32.8% during the forecast period
May 02, 2025 – Growing scientific validation and research investments is a key driver driving microbiome therapeutics market revenue growth. On March 2023, MIG Capital AG, one of Germany’s leading venture capital firms, stated that it has invested in mbiomics GmbH, a pioneering microbiome biotech company producing the first generation of effective microbiome-based therapies, as part of the first close of a Euro 13 million Series A investment. MIG led the financing, with participation from High-Tech Gründerfonds, Bayern Kapital, and a group of private seed investors. mbiomics plans to use the cash to form strategic alliances, considerably expand its Munich laboratory facilities and R&D teams in Germany, and perhaps extend its US operations.
Rising burden of chronic and lifestyle-related diseases is another key driver driving microbiome therapeutics market. According to the American Liver Association, Non-alcoholic Fatty Liver Disease (NAFLD) is believed to affect 100 million people in the United States, or approximately 25%. NAFLD is the most common form of liver disease in children, and it has more than doubled in the last 20 years. NAFLD affects around 18% of pregnant women, and pregnancy can exacerbate pre-existing NAFLD due to typical hormonal changes, primarily increased estrogen and pregnancy’s natural insulin resistance.
The primary issue in the field of microbiome treatments is identifying bacteria to address disease complexity. Different microbial strains are appropriate for different treatment techniques based on their ability to survive in the body. The efficacy of microbiome therapies has long been questioned under a variety of conditions. Furthermore, microbiome therapeutic research has mostly been conducted on rodent models, and human trials will require further work.
Key Highlights:
- Probiotic segment is expected to register the fastest growth rate over the forecast period. Probiotic strains are well-known for improving human health, the immune system, inflammation, and a variety of digestive tract diseases. Probiotics effectively reduce the growth of strong microbial pathogens, including cancer-inducing microorganisms, in the human gut by producing antimicrobial peptides and organic acids such as acetic, lactic, and propionic acid. On October 2024, Probi introduced Probi Sense, a brand-new probiotic dietary supplement that reduces stress and improves mental health. Probi Sense includes Probi’s proprietary and well-documented lactic acid bacteria strain Lactiplantibacillus plantarum HEAL9 (HEAL9), as well as zinc, iodine, and magnesium. The product, backed by four clinical studies confirming its good effects, is aimed to improve mental well-being by maintaining normal memory, focus, and lowering weariness.
- Oncology segment is expected to account for the highest revenue growth during the forecasted period. According to the NCBI report, Non-Small Cell Lung Cancer (NSCLC) accounts for over 85% of all lung cancers. At the time of diagnosis, 20% of patients had localized illness, 25% had regional metastases, and 55% had distant spread of disease. On June 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies by harnessing its expertise in the microbiome-immunomodulation axis, has completed its Euro 24 million (USD 26 million) Series A funding round. This includes a final Euro 8 million extension, which will support the continued clinical development of its therapeutic pipeline, including multiple clinical trials for EXL01—a novel immunotherapy targeting cancer and infectious diseases.
- North America accounted for the largest market revenue share in the microbiome therapeutics market in 2024 due to rising burden of chronic and lifestyle-related diseases and growing scientific validation and research investments. On May 2023, Recipharm, a global contract development and manufacturing organization (CDMO), has announced that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US Food and Drug Administration (FDA) to manufacture VOWST, a breakthrough orally administered fecal microbiota product for the prevention of Clostridioides difficile recurrent infection (CDI) in adults following antibacterial treatment for recurrent CDI.
- Some major companies in the market report include Seres Therapeutics, BIOSE INDUSTRIE, BiomeSense, Rebiotix Inc., Infant Bacterial Therapeutics AB, MaaT Pharma SA, Enterome, Vedanta Biosciences, Freya Biosciences, Finch Therapeutics Group, Inc, Axial Therapeutics, Inc., Genetic Analysis, Alveolus Bio, Microba Life Sciences, Siolta Therapeutics, Altis Biosystems, and Others.
- On March 2024, Siolta Therapeutics, a clinical-stage biotech startup, has announced the closing of a USD 12 million Series C funding round. The money raised in this round will go toward the clinical development of Siolta’s principal product, STMC-103H, a defined-consortia Live Biotherapeutic Product (LBP) aimed at preventing the onset of atopic illnesses in infants.
- On December 2023, Ferring Pharmaceuticals and Zurich-based microbiome translation startup PharmaBiome have launched a research and development agreement to advance innovative microbiome-based biotherapeutics in gastroenterology. The agreement grants Ferring exclusive rights to develop, manufacture, and commercialize next-generation microbiome-based medicines in the field of gastroenterology originating from the collaboration.
Unlock the key to transforming your business strategy with our Microbiome Therapeutics Market insights:
Navistrat Analytics has segmented microbiome therapeutics market based on product type, mode of administration, therapeutic area, and end-use:
- Product Type Outlook (Revenue, USD Million; 2022-2032)
- Probiotics
- Prebiotics
- Synbiotics
- Live Biotherapeutic Products (LBPs)
- Fecal Microbiota Transplantation (FMT)
- Others
- Mode of Administration Outlook (Revenue, USD Million; 2022-2032)
- Oral Capsules/Tablets
- Rectal
- Injectable
- Others
- Therapeutic Area Outlook (Revenue, USD Million; 2022-2032)
- Gastrointestinal Disorders
- Clostridium difficile infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Irritable Bowel Syndrome (IBS)
- Others
- Metabolic Disorders
- Obesity
- Type 2 Diabetes
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Others
- Oncology
- Melanoma
- Non-small cell lung cancer
- Lymphomas
- Autoimmune Disorders
- Neurological Disorders
- Infectious Diseases
- Others
- Gastrointestinal Disorders
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Hospitals & Clinics
- Research Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Others
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America